drugset / Trial / NCT00002679

Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer

NCT00002679

Phase 2 Completed 89 enrolled Yale University
Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of high-dose sequential chemotherapy as adjuvant therapy in treating patients with stage II or stage III breast cancer who have four or more positive axillary lymph nodes.

Timeline

Start
1994-02
Primary completion
2002-01
Completion
2002-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified
Subject Doxorubicin Other / unclassified
Subject Paclitaxel Small molecule
Background Tamoxifen Small molecule
Background filgrastim Protein / enzyme biologic

Indications